Chikungunya Vaccines

Authored by
Last reviewed
November 2, 2021

Chikungunya Vaccines

Like all vaccines under development, Chikungunya vaccine candidates investigate various technologies, such as live-attenuated virus vaccines, inactivated viral vaccines, recombinant viral vaccines, chimeric-alphavirus candidates, DNA vaccines, and virus-like particles, which focus on optimizing the balance between immunogenicity and safety.

As of November 2, 2021, 2021, the U.S. FDA has not approved a Chikungunya vaccine.

The ECDC reported about 185,000 Chikungunya cases have been reported in 2021, the majority from Brazil (110,858) and India (65,203).

Chikungunya Vaccine Candidates

VLA1553 is a monovalent, single dose, live-attenuated vaccine candidate. VLA1553 is based on an infectious clone (CHIKV LR2006-OPY1) attenuated by deleting a significant part of the gene encoding the non-structural replicase complex protein nsP3 for protection against various Chikungunya virus outbreak phylogroups and strains. VLA1553 is showing fully sustained titers one year after a single vaccination, says Valneva SE.

CHIKV-VLP vaccine candidate is a multi-protein structure that mimics the organization and conformation of naturally occurring viruses without the viral genome, promoting a more robust immune response and increased antibody production. The CHIKV VLP vaccine candidate is licensed from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. In addition, it received Fast Track designation from the U.S. Food and Drug Administration in May 2018.

MV-CHIK is a Chikungunya vaccine candidate utilizing Themis' measles vector platform. MV-CHIK consists of a recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. In addition, Themis' vaccination vector can incorporate large recombinant genes coding for selected antigens into its genome. 

mRNA-1944 encodes a fully human IgG antibody isolated initially from B cells of a patient with a prior history of potent immunity against Chikungunya infection. It comprises two mRNAs that encode this anti-Chikungunya antibody's heavy and light chains within lipid nanoparticle technology.

Chikungunya Vaccine News

November 2, 2021 - Local media in Mumbi India confirmed about 48 Chikungunya cases during 2021.

October 19, 2021 - The U.S. CDC reported 16 chikungunya virus disease cases in travelers returning from affected areas.

October. 15, 2021 - Emergent BioSolutions Inc. announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogenicity of the company's investigational chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, in a single dose. CHIKV VLP is the only VLP-based vaccine currently in clinical development for active immunization against chikungunya disease.

August 5, 2021 -  Valneva SE announced positive topline results from the Phase 3 pivotal trial of its chikungunya vaccine candidate, VLA1553. The trial, involving 4,115 adults, aged 18 years and above, across 44 sites in the U.S., met its primary endpoint inducing protective CHIKV neutralizing antibody titers in 98.5% of participants 28 days after receiving a single shot (264 of 268 subjects from the per-protocol subgroup tested for immunogenicity, 95%CI: 96.2-99.6). In addition, the seroprotection rate result of 98.5% exceeded the 70% threshold (for non-acceptance) agreed with the U.S. FDA. 

September 12, 2019 - Moderna, Inc. announced positive data in the first analysis of safety and activity in its Phase 1 study evaluating escalating doses of mRNA-1944 administered via intravenous infusion in healthy adults. mRNA-1944 encodes for an antibody (CHKV-24) with activity against the chikungunya virus.

Note: This information has been fact-checked by healthcare providers.